Nanobiotix S.A. (NANO.PA)
EUR 3.48
(1.93%)
EUR 3.48
(1.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -24.71 Million EUR | -269.39% |
| 2022 | 14.59 Million EUR | 138.5% |
| 2021 | -37.9 Million EUR | 45.99% |
| 2020 | -70.17 Million EUR | -843.98% |
| 2019 | 9.43 Million EUR | 160.15% |
| 2018 | -15.68 Million EUR | 63.09% |
| 2017 | -42.48 Million EUR | -176.03% |
| 2016 | -15.39 Million EUR | -24.1% |
| 2015 | -12.4 Million EUR | 59.55% |
| 2014 | -30.66 Million EUR | -687.18% |
| 2013 | -3.89 Million EUR | 64.36% |
| 2012 | -10.92 Million EUR | -14221.16% |
| 2011 | -76.31 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -21.85 Million EUR | 0.0% |
| 2023 FY | -24.71 Million EUR | -269.39% |
| 2023 Q4 | -24.71 Million EUR | 0.0% |
| 2023 Q2 | 32.37 Million EUR | 0.0% |
| 2022 Q2 | -17.91 Million EUR | 0.0% |
| 2022 FY | 14.59 Million EUR | 138.5% |
| 2022 Q4 | 14.59 Million EUR | 0.0% |
| 2021 Q2 | -51.61 Million EUR | 0.0% |
| 2021 FY | -37.9 Million EUR | 45.99% |
| 2021 Q4 | -37.9 Million EUR | 0.0% |
| 2020 Q2 | 25.24 Million EUR | 0.0% |
| 2020 FY | -70.17 Million EUR | -843.98% |
| 2020 Q4 | -70.17 Million EUR | 0.0% |
| 2019 Q2 | -7.03 Million EUR | 0.0% |
| 2019 FY | 9.43 Million EUR | 160.15% |
| 2019 Q4 | 9.43 Million EUR | 0.0% |
| 2018 FY | -15.68 Million EUR | 63.09% |
| 2018 Q2 | -28.66 Million EUR | 0.0% |
| 2018 Q4 | -15.68 Million EUR | 0.0% |
| 2017 FY | -42.48 Million EUR | -176.03% |
| 2017 Q4 | -42.48 Million EUR | 0.0% |
| 2017 Q2 | -25.98 Million EUR | 0.0% |
| 2016 Q2 | -20.44 Million EUR | 0.0% |
| 2016 FY | -15.39 Million EUR | -24.1% |
| 2016 Q4 | -15.39 Million EUR | 0.0% |
| 2015 FY | -12.4 Million EUR | 59.55% |
| 2015 Q4 | -12.4 Million EUR | 0.0% |
| 2015 Q2 | -20.1 Million EUR | 0.0% |
| 2014 Q4 | -30.66 Million EUR | 0.0% |
| 2014 Q2 | -25.68 Million EUR | 0.0% |
| 2014 FY | -30.66 Million EUR | -687.18% |
| 2013 Q4 | -3.89 Million EUR | 0.0% |
| 2013 Q2 | -6.81 Million EUR | 0.0% |
| 2013 FY | -3.89 Million EUR | 64.36% |
| 2012 FY | -10.92 Million EUR | -14221.16% |
| 2012 Q4 | -10.92 Million EUR | 0.0% |
| 2011 FY | -76.31 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -3361.905% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 87.419% |
| Adocia SA | 127 Thousand EUR | 19562.992% |
| Aelis Farma SA | -16.19 Million EUR | -52.656% |
| Biophytis S.A. | 2.7 Million EUR | 1014.465% |
| Advicenne S.A. | 12.17 Million EUR | 303.023% |
| genOway Société anonyme | 2.97 Million EUR | 931.425% |
| IntegraGen SA | -709.74 Thousand EUR | -3382.64% |
| Medesis Pharma S.A. | 1.15 Million EUR | 2234.155% |
| Neovacs S.A. | -237.08 Thousand EUR | -10325.709% |
| NFL Biosciences SA | -2.27 Million EUR | -986.09% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 667.381% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -2876.107% |
| Sensorion SA | 1.37 Million EUR | 1893.47% |
| Theranexus Société Anonyme | 2.44 Million EUR | 1111.311% |
| TME Pharma N.V. | -1.07 Million EUR | -2190.825% |
| Valbiotis SA | -18.13 Million EUR | -36.27% |
| TheraVet SA | 12.78 Thousand EUR | 193435.941% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 1233.853% |
| argenx SE | -1.83 Billion EUR | 98.654% |
| BioSenic S.A. | 28.04 Million EUR | 188.14% |
| Celyad Oncology SA | -6.1 Million EUR | -305.08% |
| DBV Technologies S.A. | -114.95 Million USD | 78.498% |
| Galapagos NV | -157.2 Million EUR | 84.277% |
| Genfit S.A. | -7.61 Million EUR | -224.767% |
| GeNeuro SA | 5.91 Million EUR | 518.212% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 1.569% |
| Innate Pharma S.A. | -30.71 Million EUR | 19.517% |
| Inventiva S.A. | 10.48 Million EUR | 335.656% |
| MaaT Pharma SA | -10.2 Million EUR | -142.215% |
| MedinCell S.A. | 39.5 Million EUR | 162.576% |
| Onward Medical N.V. | -12.89 Million EUR | -91.702% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 1828.128% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 191.113% |
| Oxurion NV | 10.71 Million EUR | 330.794% |
| Pharming Group N.V. | 99.4 Million EUR | 124.867% |
| Poxel S.A. | 44.55 Million EUR | 155.473% |
| GenSight Biologics S.A. | 16.29 Million EUR | 251.7% |
| Transgene SA | -14.4 Million EUR | -71.546% |
| Financière de Tubize SA | 78.62 Million EUR | 131.438% |
| UCB SA | 2.17 Billion EUR | 101.135% |
| Valneva SE | 82.73 Million EUR | 129.876% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | -33.438% |